Publications by authors named "Mohsin Soleja"
Background: Adjuvant chemotherapy for stage III colon cancer is underutilized in the United States. The aim of this study was to assess the use of adjuvant chemotherapy in younger and medically fit patients and analyze the socioeconomic factors associated with its utilization.
Methods: Using the National Cancer Database from 2004 to 2015, we selected stage III colon cancer patients between age 18 to 65, Charlson-Deyo Comorbidity Index (CDCI) of 0 or 1, and those that survived at least 12 months after surgery.
Article Synopsis
- Isolated central nervous system lymphomatoid granulomatosis (CNS-LYG) can closely resemble aggressive glioblastomas, making diagnosis challenging.
- The case discussed involves a patient with CNS-LYG alongside immune thrombocytopenia, which is a condition characterized by low platelet counts.
- Treatment was successful using rituximab, a drug that targets certain immune cells, combined with ultra-low-dose radiation therapy.
An evaluation of fulvestrant for the treatment of metastatic breast cancer.
Expert Opin Pharmacother
October 2019
: Fulvestrant is currently the only selective estrogen receptor degrader (SERD) that is approved for clinical use in estrogen receptor (ER) positive advanced breast cancer (ABC). The drug is approved as single-agent therapy in the first and second-line setting of metastatic ER-positive breast cancer. : In this review, the authors review the preclinical studies that were pivotal in the development of fulvestrant, the pharmacologic properties of the drug, and the key clinical trials that resulted in its approval for clinical use.
View Article and Find Full Text PDFHER2 is over-expressed or amplified in 15-20% of breast cancer. Significant progress has been made in the treatment of metastatic HER2+ breast cancer. This is largely due to successful targeting of the HER2 pathway.
View Article and Find Full Text PDF